Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

AVBP

ArriVent BioPharma Inc.

Jul 26 • 04:00PM ET

22.38

Dollar change +1.24
Percentage change 5.87	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Financials • Options Chain • Save to Portfolio • Create Alert

Held by: VTI IWM VXF IWO SCHA IWN VTWO SBIO IWC SCHB

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-2.23	Insider Own	41.04%	Shs Outstand	33.49M	Perf Week	19.23%
Market Cap	749.51M	Forward P/E	-	EPS next Y	-2.93	Insider Trans	15.93%	Shs Float	19.75M	Perf Month	32.04%
Income	-74.58M	PEG	-	EPS next Q	-0.64	Inst Own	45.09%	Short Float	8.21%	Perf Quarter	44.02%
Sales	0.00M	P/S	-	EPS this Y	90.60%	Inst Trans	-	Short Ratio	27.92	Perf Half Y	-
Book/sh	9.49	P/B	2.36	EPS next Y	3.64%	ROA	-40.08%	Short Interest	1.62M	Perf Year	-
Cash/sh	9.48	P/C	2.36	EPS next 5Y	-	ROE	-42.57%	52W Range	14.35 - 25.95	Perf YTD	11.90%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-	ROI	-23.46%	52W High	-13.76%	Beta	-
Dividend TTM	-	Quick Ratio	32.82	Sales past 5Y	0.00%	Gross Margin	-	52W Low	55.96%	ATR (14)	1.33
Dividend Ex-Date	-	Current Ratio	32.82	EPS Y/Y TTM	-	Oper. Margin	0.00%	RSI (14)	73.18	Volatility	7.15% 7.10%
Employees	40	Debt/Eq	0.00	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.00	Target Price	31.00
Option/Short	No / Yes	LT Debt/Eq	0.00	EPS Q/Q	-43.09%	Payout	-	Rel Volume	1.30	Prev Close	21.14
Sales Surprise	-	EPS Surprise	35.02%	Sales Q/Q	-	Earnings	May 08 BMO	Avg Volume	58.04K	Price	22.38
SMA20	17.84%	SMA50	18.83%	SMA200	18.80%	Trades		Volume	75,165	Change	5.87%

Date	Action	Analyst	Rating Change	Price Target Change
Jul-22-24	Initiated	Oppenheimer	Outperform	$35
Apr-30-24	Initiated	H.C. Wainwright	Buy	$25
Feb-20-24	Initiated	Jefferies	Buy	$35
Feb-20-24	Initiated	Goldman	Buy	$27
Feb-20-24	Initiated	Citigroup	Buy	$30

Jun-05-24 07:00AM	ArriVent Announces a Multi-Target ADC Collaboration with Alphamab (GlobeNewswire)
May-16-24 04:05PM	ArriVent Appoints John Hohneker, M.D., to its Board of Directors (GlobeNewswire)
May-08-24 12:54PM	AVBP Stock Earnings: ArriVent BioPharma Beats EPS for Q1 2024 (InvestorPlace)
08:00AM	ArriVent BioPharma Reports First Quarter 2024 Financial Results (GlobeNewswire)
Apr-22-24 04:05PM	ArriVent Appoints Kristine Peterson to its Board of Directors (GlobeNewswire)
04:05PM	Loading…
Mar-28-24 04:05PM	ArriVent BioPharma Reports Full Year 2023 Financial Results (GlobeNewswire)
Feb-05-24 12:59PM	Hedge Fund and Insider Trading News: Bill Ackman, Ken Griffin, Paul Tudor Jones, Julian Robertson, Charles Edwards, Arcus Biosciences, Inc. (RCUS), Arrivent Biopharma Inc (AVBP), and More (Insider Monkey)
Jan-25-24 09:30PM	ArriVent Announces Pricing of Upsized Initial Public Offering (GlobeNewswire)

Arrivent Biopharma, Inc. is a clinical-stage biopharmaceutical company. It focuses on identifying, licensing and globalizing biopharma innovations from around the world to deliver important medicines to patients. The company was founded Zheng Bin Yao and Stuart Lutzker on April 14, 2021 and is headquartered in Newtown Square, PA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
HILLHOUSE INVESTMENT MANAGEMEN	10% Owner	Jan 30 '24	Buy	18.00	555,555	9,999,990	4,484,672	Feb 01 04:47 PM
HEALY JAMES	Director	Jan 30 '24	Buy	18.00	444,444	7,999,992	1,696,752	Jan 31 04:10 PM
GORDON CARL L	Director	Jan 30 '24	Buy	18.00	444,444	7,999,992	1,513,664	Jan 31 04:11 PM
ORBIMED ADVISORS LLC	Director	Jan 30 '24	Buy	18.00	444,444	7,999,992	1,513,664	Jan 31 04:12 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

AVBP

ArriVent BioPharma Inc.

Upgrade your FINVIZ experience